BioCryst Pharmaceuticals, Inc.
BCRX
$7.97
$0.121.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 599.82M | 557.51M | 503.49M | 450.71M | 412.58M |
| Total Other Revenue | -- | 766.00K | 1.81M | 5.70M | 8.22M |
| Total Revenue | 599.82M | 557.51M | 503.49M | 450.71M | 412.58M |
| Cost of Revenue | 190.38M | 187.89M | 181.02M | 186.94M | 198.49M |
| Gross Profit | 409.43M | 369.62M | 322.46M | 263.77M | 214.09M |
| SG&A Expenses | 333.34M | 315.42M | 289.29M | 266.31M | 249.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 523.72M | 503.31M | 470.31M | 453.26M | 448.36M |
| Operating Income | 76.10M | 54.20M | 33.17M | -2.54M | -35.78M |
| Income Before Tax | -6.62M | -32.19M | -51.18M | -86.95M | -124.13M |
| Income Tax Expenses | 2.16M | 3.52M | 2.29M | 1.93M | -308.00K |
| Earnings from Continuing Operations | -8.78 | -35.71 | -53.47 | -88.88 | -123.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.78M | -35.71M | -53.47M | -88.88M | -123.82M |
| EBIT | 76.10M | 54.20M | 33.17M | -2.54M | -35.78M |
| EBITDA | 79.17M | 57.24M | 36.21M | 469.00K | -33.21M |
| EPS Basic | -0.04 | -0.17 | -0.26 | -0.43 | -0.61 |
| Normalized Basic EPS | 0.00 | -0.08 | -0.15 | -0.26 | -0.37 |
| EPS Diluted | -0.05 | -0.18 | -0.26 | -0.43 | -0.61 |
| Normalized Diluted EPS | 0.00 | -0.09 | -0.15 | -0.26 | -0.37 |
| Average Basic Shares Outstanding | 835.96M | 832.69M | 829.59M | 826.78M | 820.80M |
| Average Diluted Shares Outstanding | 862.41M | 849.43M | 835.97M | 826.78M | 820.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |